美国食品和药物管理局批准使用Benlysta治疗狼性炎的儿童, FDA approves Benlysta for children with lupus nephritis, first biologic for this condition.

美国食品和药物管理局批准Benlysta,一种用于皮下注射的自动注射器,适用于5岁及以上活跃狼性炎患者. The FDA has approved Benlysta, an autoinjector for subcutaneous injection, for patients aged 5 and older with active lupus nephritis. 这是首个获批用于治疗系统性红斑狼疮和狼疮肾炎的生物制剂。 It's the first approved biologic for both systemic lupus erythematosus and lupus nephritis. 常见的不良反应包括严重感染、恶心、腹泻、发烧、喉炎、支气管炎、失眠、疼痛、抑郁、偏头痛和注射现场反应。 Common adverse reactions include serious infections, nausea, diarrhea, fever, throat inflammation, bronchitis, insomnia, pain, depression, migraine, and injection site reactions.